IVISense™ Gastrointestinal 750 (GastroSense™ 750) is a near-infrared, fluorescently-labeled macromolecule that can be used to monitor the effects of disease or drugs on gastric motility and or gastric emptying. It may also be used as an anatomical marker for the gastrointestinal tract.
For research use only. Not for use in diagnostic procedures.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Accurately determining gastric emptying rates is crucial for understanding the physiological mechanisms underlying alterations in gastric motility. Additionally, a pharmacological agent’s effects on gastric emptying can determine its potential as a therapeutic. Currently, the methods used for preclinical determination of gastric emptying rates involve terminal assessment of dye or radioactive tracers within the stomach. These methods require the use of many animals, incurring high financial and time costs. IVISense Gastrointestinal 750 fluorescent probe enables non-invasive in vivo visualization and quantification of the effects of disease or drugs on the GI tract.Tips:
IVISense Gastrointestinal 750 fluoresscent probe may also be administered as part of a solid diet by applying the reconstituted solution to egg yolk. When added to a solid diet it may be easier to reconstitute the vial of the probe with 300 µL of 1x PBS and use 25 µL per mouse. IVISense Gastrointestinal fluorescent agent remains localized in the GI tract and is not absorbed into the bloodstream.
|Fluorescent Agent Type||Targeted|
|Optical Imaging Classification||Fluorescence Imaging|
|Product Brand Name||IVISense|
|Quantity in a Package Amount||1.0 Units|
|Unit Size||1 Vial (10 doses)|
|Wave Length||750 nm|
The accurate quantitation of gastric emptying is crucial,for understanding the physiological, pathological and,pharmacological mechanisms underlying gastric motility,both clinically and in animal studies. Current methods,used for determining gastric emptying rates in small animals,are either terminal or involve radioactive tracers, incurring,high financial and time cost. We have developed a novel,near-infrared (NIR) fluorescent imaging agent, GastroSense™ 750, to monitor and quantitate gastric,emptying rates in murine models in vivo, non-invasively, and in real time. The imaging agent is,comprised of an acid-stable NIR fluorophore conjugated to a non-absorbable pharmacokinetic,modifier designed to be formulated in liquid or incorporated into a solid meal. Using female,8 week old BALB/c mice recipients, 0.25 nmol GastroSense 750 was orally gavaged in liquid,formulation (PBS) or fed in egg yolk, an experimental approach designed to detect changes in,gastric emptying. In vivo 3D fluorescent imaging and quantitation using the FMT®
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.
Fluorescence molecular imaging is the visualization of cellular and biological function in vivo to gain deeper insights into disease processes and treatment effects. Designing an effective study from the beginning can help save time and resources.
Learn about several important best practices, from proper probe selection to study design to imaging technique tips and tricks needed to generate meaningful biological information from your in vivo fluorescence imaging studies.
GastroSense™ 750 is a near-infrared, fluorescently-labeled macromolecule that may be used to monitor the effects of disease or drugs on gastric motility and or gastric emptying. It may also be used as an anatomical marker for the gastrointestinal tract.
GastroSense 750 fluorescent agent imaging protocol outlining procedures for preparing mice for imaging, preparing GastroSense 750 imaging agent, injection agent into mice, and imaging mice on IVIS and/or FMT imaging systems.
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.